Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
MDXG 
MiMedx Group Inc (MDXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: MDXG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.2
1 Year Target Price $12.2
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.08% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.02B USD | Price to earnings Ratio 25.56 | 1Y Target Price 12.2 |
Price to earnings Ratio 25.56 | 1Y Target Price 12.2 | ||
Volume (30-day avg) 5 | Beta 1.64 | 52 Weeks Range 5.79 - 9.71 | Updated Date 12/28/2025 |
52 Weeks Range 5.79 - 9.71 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.38% | Operating Margin (TTM) 19.51% |
Management Effectiveness
Return on Assets (TTM) 11.98% | Return on Equity (TTM) 19.44% |
Valuation
Trailing PE 25.56 | Forward PE 19.53 | Enterprise Value 898035897 | Price to Sales(TTM) 2.6 |
Enterprise Value 898035897 | Price to Sales(TTM) 2.6 | ||
Enterprise Value to Revenue 2.28 | Enterprise Value to EBITDA 13.15 | Shares Outstanding 148102159 | Shares Floating 109663725 |
Shares Outstanding 148102159 | Shares Floating 109663725 | ||
Percent Insiders 1.66 | Percent Institutions 71.89 |
Upturn AI SWOT
MiMedx Group Inc
Company Overview
History and Background
MiMedx Group Inc. was founded in 1986 and has evolved into a company focused on regenerative medicine, utilizing placental tissue allografts for wound healing and surgical applications. Key milestones include the development of their AmnioWrapu00ae and EpiFixu00ae products and navigating regulatory and compliance challenges. The company has undergone significant leadership changes and strategic realignments to focus on its core regenerative medicine offerings.
Core Business Areas
- Wound Healing: MiMedx's primary focus is on developing and commercializing regenerative amniotic tissue-based allografts for the treatment of chronic and acute wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
- Surgical Applications: The company also offers amniotic membrane allografts for surgical use, aimed at improving surgical outcomes and reducing complications in various procedures, particularly in ophthalmology and orthopedic surgeries.
Leadership and Structure
The leadership structure of MiMedx typically includes a CEO, CFO, Chief Medical Officer, and heads of various operational and commercial divisions. The organizational structure is designed to support research and development, manufacturing, sales, marketing, and regulatory affairs within the highly regulated biotechnology sector.
Top Products and Market Share
Key Offerings
- AmnioWrapu00ae: A dehydrated amniotic membrane allograft used for the treatment of chronic and complex wounds. It is designed to promote natural healing processes. Competitors in this space include companies offering other advanced wound care solutions such as Smith & Nephew, Mu00f6lnlycke, and Integra LifeSciences, as well as other placental tissue allograft providers.
- EpiFixu00ae: Another dehydrated amniotic membrane allograft, similar to AmnioWrapu00ae, used for wound management, particularly for lower extremity ulcers. Its competitive landscape is the same as AmnioWrapu00ae.
- BioFixu00ae: Amniotic tissue allografts for surgical applications, including orthopedics and ophthalmology, to aid in tissue repair and reduce inflammation. Competitors include companies specializing in surgical biologics and tissue matrices.
Market Dynamics
Industry Overview
MiMedx operates in the regenerative medicine and advanced wound care markets, which are characterized by growing demand due to an aging population, increasing prevalence of chronic diseases like diabetes, and advancements in biomaterials and tissue engineering. The industry is highly regulated and competitive, with a focus on clinical efficacy and cost-effectiveness.
Positioning
MiMedx positions itself as a leader in the use of amniotic tissue allografts for regenerative medicine. Its competitive advantages lie in its proprietary processing technology for preserving the natural properties of placental tissue, its established sales force, and its focus on clinical evidence generation. However, it faces competition from other advanced wound care modalities and regenerative medicine technologies.
Total Addressable Market (TAM)
The global advanced wound care market is substantial and projected to grow significantly, with estimates in the tens of billions of dollars. The regenerative medicine segment within this market is also expanding rapidly. MiMedx is positioned to capture a share of this TAM by focusing on its niche within amniotic tissue-based allografts for chronic wounds and surgical applications.
Upturn SWOT Analysis
Strengths
- Proprietary processing technology for placental tissue allografts.
- Established product portfolio with recognized brand names (AmnioWrapu00ae, EpiFixu00ae).
- Focus on a high-growth segment within regenerative medicine and wound care.
- Dedicated sales force with experience in the healthcare sector.
Weaknesses
- Historical regulatory and compliance challenges have impacted reputation and operations.
- Reliance on a specific type of biological tissue can present supply chain considerations.
- Need for continued investment in clinical trials to demonstrate long-term efficacy and cost-effectiveness.
Opportunities
- Expansion into new therapeutic areas and surgical specialties.
- Growing global demand for advanced wound care and regenerative medicine solutions.
- Potential for strategic partnerships or acquisitions to broaden product offerings or market reach.
- Leveraging data from real-world evidence to support product value propositions.
Threats
- Intense competition from other regenerative medicine and advanced wound care companies.
- Changes in healthcare reimbursement policies and payer coverage.
- Stringent regulatory requirements and potential for new regulations.
- Emergence of alternative or superior therapeutic technologies.
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Mu00f6lnlycke Health Care (part of Investor AB)
- Convatec Group (CTEC)
- Integra LifeSciences (IART)
- Organogenesis Holdings Inc. (ORGO)
Competitive Landscape
MiMedx's advantages include its specialization in amniotic tissue allografts and a proprietary processing method. However, it faces disadvantages in the form of intense competition from larger, more diversified medical device companies and potentially higher price points for its specialized products compared to some conventional wound care options. Competitors often leverage broader product portfolios and established relationships across multiple healthcare segments.
Growth Trajectory and Initiatives
Historical Growth: MiMedx has experienced periods of significant revenue growth, driven by the adoption of its amniotic tissue allografts. However, this growth has also been subject to fluctuations due to market dynamics, regulatory scrutiny, and strategic shifts.
Future Projections: Future growth is expected to be propelled by the increasing demand for regenerative medicine and advanced wound care. Analyst projections often consider factors such as new product introductions, market penetration in existing and new geographies, and successful clinical trial outcomes.
Recent Initiatives: Recent initiatives likely include strengthening compliance programs, optimizing manufacturing processes, expanding the sales force, and investing in clinical research to further validate the efficacy and economic benefits of their products.
Summary
MiMedx Group Inc. is a player in the regenerative medicine and advanced wound care market, with a strong focus on amniotic tissue allografts. Its key strengths lie in its proprietary technology and established products, while facing challenges from competition and past regulatory issues. The company has opportunities for growth through market expansion and new applications, but must remain vigilant against emerging threats and evolving reimbursement landscapes.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Websites
- Industry Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This JSON output is a structured overview based on publicly available information. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data and competitor information are estimates and may vary based on reporting methodologies and timeframes. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MiMedx Group Inc
Exchange NASDAQ | Headquaters Marietta, GA, United States | ||
IPO Launch date 2007-08-22 | CEO & Director Mr. Joseph H. Capper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 837 | Website https://www.mimedx.com |
Full time employees 837 | Website https://www.mimedx.com | ||
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.